Turmeric (Supplement) for Cancer Risk Reduction

Research suggests that curcumin, the active compound in turmeric, has shown some promise in preclinical settings related to cancer risk reduction, though the human evidence remains limited and the overall picture is mixed. Animal studies indicate that curcumin may reduce precancerous colon lesions by modulating inflammation-related markers, and laboratory work has explored its use in combination approaches targeting aggressive breast cancer cells, but these findings have not been replicated in rigorous human trials. One systematic review of randomized controlled trials noted that a multi-ingredient supplement containing turmeric showed potentially beneficial effects in prostate cancer patients, but the review emphasized that the evidence base as a whole is too weak and inconsistently designed to draw firm conclusions. Adding further complexity, a 2025 study raised a safety concern, finding that curcumin may impair a DNA repair process in both cancerous and healthy cells, which could interact harmfully with certain cancer treatments — a reminder that the research on turmeric and cancer is still developing and that its effects are not uniformly beneficial across all contexts.